• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,034.42 -829.29
( -1.08%)
Global Indices
Nasdaq
46,702.98 -735.30
(-1.55%)
Dow Jones
6,694.68 -102.12
(-1.50%)
Hang Seng
54,230.47 -794.90
(-1.44%)
Nikkei 225
10,300.41 -53.36
(-0.52%)
Forex
USD-INR
91.90 -0.24
(-0.26%)
EUR-INR
106.87 0.29
(0.27%)
GBP-INR
123.51 0.42
(0.34%)
JPY-INR
0.58 0.00
(0.09%)

EQUITY - MARKET SCREENER

Esprit Stones Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
92831
INE0SBP01018
57.8117766
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ESPRIT
17.32
144.84
EPS(TTM)
Face Value()
Div & Yield %
3.81
10
0
 

Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.